|
Post by dreamboatcruise on Apr 1, 2015 10:46:07 GMT -5
... As Bobw pointed out, those who lent their shares out no longer own the shares, thus do not have voting rights. Those voting rights belong to the 'shorts.' does anyone know when the date of record for proxy (ownership of shares) is- I have searched the 10-K to no avail; sent a request in to Matt thru the IR website (no reply for 4 days) Anyone have his direct email? I want to recall my shares from the lending program before the shorts get proxy for them You may want to recall so that you can vote, but if someone shorts the shares they are not the ones that get to vote, it is the long that has bought the shares from the short that holds voting rights. When people recall their lent shares, the shares and voting rights either come from 1) other longs willing to lend or 2) longs willing to sell.
|
|
|
Post by jpg on Apr 7, 2015 2:22:56 GMT -5
does anyone know when the date of record for proxy (ownership of shares) is- I have searched the 10-K to no avail; sent a request in to Matt thru the IR website (no reply for 4 days) Anyone have his direct email? I want to recall my shares from the lending program before the shorts get proxy for them You may want to recall so that you can vote, but if someone shorts the shares they are not the ones that get to vote, it is the long that has bought the shares from the short that holds voting rights. When people recall their lent shares, the shares and voting rights either come from 1) other longs willing to lend or 2) longs willing to sell. It certainly would be ironic if our collectively lent shares be voted, however symbolically against us?
|
|
|
Post by gomnkd on Apr 7, 2015 9:10:22 GMT -5
Forget your voting. You are like a voter in non-swing state. Your votes don't matter. collectively individual investors (excluding institutions and Al Mann) will own less than 15% of stock.
|
|
|
Post by jpg on Apr 7, 2015 9:11:33 GMT -5
Good point...
|
|
|
Post by kball on Apr 7, 2015 9:43:08 GMT -5
Forget your voting. You are like a voter in non-swing state. Your votes don't matter. collectively individual investors (excluding institutions and Al Mann) will own less than 15% of stock. Agree with regard to voting. If you want your voice heard, be prepared to attend meeting and hope theres a microphone for questions. Then, state your name (and # of shares along with length of time being a shareholder if so inclined) and ask a question.
|
|
|
Post by BD on Apr 7, 2015 9:45:53 GMT -5
I don't think announcing the number of shares you hold is particularly wise. It's better if all questioners are uniformly viewed as "shareholders"; announcing your position is only going to foment judgment of one sort or another in everyone else's minds.
|
|
|
Post by mnholdem on Apr 7, 2015 9:56:50 GMT -5
Is it possible to write in "MnHoldem" for head of Investor Relations? We'd have to create a new Officer position, wouldn't we?
|
|
|
Post by mnkdfan on Apr 11, 2015 1:16:09 GMT -5
I stumbled across this in depth analysis of why inhale insulin Exubera failed. After reading the article, I am in complete agreement that a common challenge exist between Exubera and Afrezza that we must overcome. It is in the delays with patients having to obtain and jumping through multiple hoops to get the lung test before getting the prescription. The below report is spot on in my opinion in stating that this logistic hurdle as a big part of Exubera's demise. Although Afrezza have much more benefits and advantages over Exubera, the uptake delay gate is this lung test and two visits to the endo before a script is written. I would hope that MNKD and Sanofi is already aware of this hurdle but it would not hurt if some of you attending the share meeting could perhaps raise this issue to the executive team or send this link to Matt P. My cube mate is type 1 and was excited about seeing his Endo to get a 10 day sample pack to try out. Little did he know that this conservative 60+ year old Endo would still make him get a lung test before giving out the 10-day sample. After waiting 2 weeks to hear from the Endo's office on where to get his lung tested, he called the office and the endo office told him to go and see his GP for doing the lung test. He then calls his GP for help and they said for him to get the test done at the hospital with not much more information regarding cost or which hospital. So frustrated, he's no longer interested in getting the sample pack. This is a big problem that can be solved and must be addressed by Sanofi/MNKD. books.google.com/books?id=airg7FXENOMC&pg=PT80&lpg=PT85&ots=QVil4tiird&focus=viewport&dq=irrational+exubera&output=html_textMNKD has a much much better product than Exubera but MNKD/Sanofi must be smarter in overcoming the logistics for expediting the lung testing and learn from the Exubera debacle. Perhaps the new CEO from Pfizer will know of this challenge and can make the needed adjustment. I hope I am wrong and the smart folks at MNKD and Sanofi is aware of this hurdle and have a plan in place. Judging from my colleague's experience, not a whole lot is yet in place. We keep saying to be patient but the script numbers can go up so much faster if a patient can get their script with one visit to their doctor instead of three visits. Is this why the Shorts think we will fail even though Afrezza is so much better than Exubera??? I think our script numbers will grow very slowly until we get the GPs that have fast access to the Spirometer testing (in office) to perform the test and give out the script the same day. MNKDFAN
|
|
|
Post by jpg on Apr 11, 2015 3:22:44 GMT -5
I stumbled across this in depth analysis of why inhale insulin Exubera failed. After reading the article, I am in complete agreement that a common challenge exist between Exubera and Afrezza that we must overcome. It is in the delays with patients having to obtain and jumping through multiple hoops to get the lung test before getting the prescription. The below report is spot on in my opinion in stating that this logistic hurdle as a big part of Exubera's demise. Although Afrezza have much more benefits and advantages over Exubera, the uptake delay gate is this lung test and two visits to the endo before a script is written. I would hope that MNKD and Sanofi is already aware of this hurdle but it would not hurt if some of you attending the share meeting could perhaps raise this issue to the executive team or send this link to Matt P. My cube mate is type 1 and was excited about seeing his Endo to get a 10 day sample pack to try out. Little did he know that this conservative 60+ year old Endo would still make him get a lung test before giving out the 10-day sample. After waiting 2 weeks to hear from the Endo's office on where to get his lung tested, he called the office and the endo office told him to go and see his GP for doing the lung test. He then calls his GP for help and they said for him to get the test done at the hospital with not much more information regarding cost or which hospital. So frustrated, he's no longer interested in getting the sample pack. This is a big problem that can be solved and must be addressed by Sanofi/MNKD. books.google.com/books?id=airg7FXENOMC&pg=PT80&lpg=PT85&ots=QVil4tiird&focus=viewport&dq=irrational+exubera&output=html_textMNKD has a much much better product than Exubera but MNKD/Sanofi must be smarter in overcoming the logistics for expediting the lung testing and learn from the Exubera debacle. Perhaps the new CEO from Pfizer will know of this challenge and can make the needed adjustment. I hope I am wrong and the smart folks at MNKD and Sanofi is aware of this hurdle and have a plan in place. Judging from my colleague's experience, not a whole lot is yet in place. We keep saying to be patient but the script numbers can go up so much faster if a patient can get their script with one visit to their doctor instead of three visits. Is this why the Shorts think we will fail even though Afrezza is so much better than Exubera??? I think our script numbers will grow very slowly until we get the GPs that have fast access to the Spirometer testing (in office) to perform the test and give out the script the same day. MNKDFAN Thank you. Very interesting. Can Sanofi help this along? There is basically demand (I've heard of many other stories like this) but the system isn't set up to make it happen. What will Sanofi do? It wouldn't take a logistics genius to figure out there might be a win win for a few regional or a national spirometry provider to team up with Sanofi which could turn around and hand out a list of cheap and quick places to get spirometries done. Not rocket science... They had 6 months to think about it but didn't? Surprising no? Kind of ironic having this extraordinary medical product but not being able to make it sell even to motivated and interested parties. This might eventually be a Harvard Business School case study of good or bad (depending on outcome obviously) management. Extraordinary product but companies to incompetent to sell it or extraordinary product and companies smart enough to figure out the logistics and turn Afrezza into a mega blockbuster. Kind of binary but realistic. The new Sanofi and Mannkind CEOs will have legacies to think about. Imagine the Sanofi CEO with 2 inhaled insulins as a track record? Interesting. What is the new CEO of 'our company' thinking? We are still very early in all this but these types of stories would make me laugh if I was not invested in the future of Afrezza and Mannkind... I obviously think they will figure this out sooner rather then later. It's not rocket science. Theoretically the hard part has been done. It's now relatively simple logistics and finding a simple win win deals with a spirometry service providers. Hopefully now the new CEOs of Sanofi and Mannkind are in place we can move forward efficiently on these simple but highly important logistics details? Sadly I'm not going to the AGM but this is the type of question we could constructively bring to the table.
|
|
|
Post by kball on Apr 11, 2015 6:06:54 GMT -5
Reasonably sure concerns like these are baked into the stock price. And the challenges are obvious and constantly being considered by the companies.
It seems a better mousetrap, perhaps one more expensive and a bit harder to locate. But for those with a mouse problem....
|
|
|
Post by gomnkd on Apr 11, 2015 9:07:42 GMT -5
I've ordered the book. The few pages I read piqued my interest.
Exubera would have succeeded in the long run, surely when 2nd gen product comes out. It could have been a 1/2 - 1 BB product.The previous mgmt was so wrong in their projections. PFE had a change in top level and new mgmt generally don't like to carry a baggage around. They have to constantly come up with excuses as to why sales are slow to pick up and it affects their credibility (read options, bonuses,call for resignation).
This explains Sanofi's strategy. Go slow, let the system warm up to accept Afrezza. It also explains the peanuts (150MM) they gave as upfront payment. I only hope Sanofi got infinite patience. This is why market is totally ignoring Rx counts. The Hakans of the world should keep cash burn to a minimum.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 11, 2015 9:50:25 GMT -5
Spirometry - heard SNY reps were carrying around billing codes in a leave behind for docs and also SNY had relationship with Spirometry mfg, SNY reps to give leads to Spirometry reps - no idea if true but implementing this program would be simple. Quality no frills Spirometer < $500 Spirometry billing codes: www.midmark.com/docs/default-source/marketing-collateral/007-0962-00.pdfgomnkd - you think US strategy was to get core group of KOLs educated on nuances of Afrezza like minimal titration / carb counting, reduced hypos, 15 min peak, out of body in 3 hrs, follow up dose an hour or two after meal / initial dose of BG levels remain too high without worry of stacking / insulin hanging around body and kicking in creating a hypo like RAAs do? Much of this is counter to what Docs know and how they have practiced medicine so docs are cautious and managing their risk. Are they working on approval and trials for label improvement in UK / Europe and then launch there and take data to change US label? Thoughts on reps focusing on Toujeo since they got early approval and Novo looks like Tresiba is back in the hunt. www.pmlive.com/pharma_news/fda_starts_review_of_novos_refiled_diabetes_pair_707145SNY was supposed to have 2 years without Tresiba competition to convert Lantus to Toujeo now looks like that won't happen.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 11, 2015 10:07:11 GMT -5
Annual meeting, I would like to know:
Does SNY have sales people exclusively dedicated to selling only Afrezza and if so, how many and at the time of the annual meeting, are these salespeople still representing Afrezza exclusively.
Depending on the answer to the above, are the SNY sales people who represent diabetes products focused exclusively on Toujeo and if so, is there definitive knowledge as to how long the Toujeo focus will last, that is, will it be based on a calendar date or sales volume of Toujeo.
Do you know YTD how many sales calls YTD SNY reps have made to exclusively pitch Afrezza (this number can be easily had from SNYs CRM system).
Should we expect to see DTC advertising in 2015 for Afrezza in the US.
Are there any studies currently underway, or will there be any studies started in the next 6 months for the purposes of improving label claims.
Anticipated launch date in UK and Europe?
|
|
|
Post by ezrasfund on Apr 11, 2015 10:27:44 GMT -5
Questions about the fill/finish lines would give us some insight into management's predictions for sales growth. Lines 2 and 3 should be in place and certified by the FDA, although Hakan's deadline for this is really June 30th (by the end of the 2nd quarter).
The question is "Have additional fill/finish line beyond these original 3 been ordered."
|
|
|
Post by mannmade on Apr 11, 2015 10:31:14 GMT -5
Questions about the fill/finish lines would give us some insight into management's predictions for sales growth. Lines 2 and 3 should be in place and certified by the FDA, although Hakan's deadline for this is really June 30th (by the end of the 2nd quarter). The question is "Have additional fill/finish line beyond these original 3 been ordered." Do they expect to be running three shifts on all three lines as they currently are for line 1?
|
|